Benzinga | Jul 21, 2021 08:07AM EDT

Zogenix Highlights Recognition Of FINTEPLA In Epilepsy & Behavior Editorial

Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that its product FINTEPLA(r) (fenfluramine) oral solution has been recognized by two distinguished clinicians in an Epilepsy & Behavior editorial titled "Raising the Bar: Fenfluramine Sets New Treatment Standards for Dravet Syndrome."